German Logistics Stock News

XTRA:TMV
XTRA:TMVSoftware

TeamViewer (XTRA:TMV) Margin Beat Reinforces Bullish Narratives Despite Share Price Discount

TeamViewer (XTRA:TMV) posted robust earnings, with net profit margins rising to 17.8% from 16.3% a year ago. Over the last five years, annual earnings have grown by 11.1%, while the most recent twelve months saw a 19.6% jump in earnings. With earnings forecast to grow by 14.1% per year and revenue expected to increase at 7.7% annually, outpacing the broader German market, investors have plenty of growth drivers to watch. At the same time, share price and financial stability risks remain part...
XTRA:GXI
XTRA:GXILife Sciences

Should FDA Approval of Lasix ONYU Prompt a Closer Look at Gerresheimer’s (XTRA:GXI) Growth Path?

On October 13, 2025, SQ Innovation received FDA approval for Lasix ONYU, a combination product featuring Gerresheimer’s proprietary on-body infusor for at-home subcutaneous drug delivery in select congestive heart failure patients. This milestone showcases Gerresheimer’s technological capabilities in advanced drug delivery devices and highlights its growing position as a full-service partner to pharmaceutical companies embracing home-based care. Next, we’ll explore how the FDA-backed rollout...
XTRA:CEC
XTRA:CECSpecialty Retail

Ceconomy’s (XTRA:CEC) Index Exit: Could Shifting Investor Demand Change Its Strategic Path?

Ceconomy AG was recently removed from the Germany Small DAX (Total Return) Index, changing its status among tracked German equities. This exclusion may affect its visibility and demand from funds that track the index, influencing the company’s relationship with institutional investors. We’ll explore how Ceconomy's index removal may impact its investment case, especially regarding its profile among index-oriented investors. We've found 18 US stocks that are forecast to pay a dividend yield of...
XTRA:GXI
XTRA:GXILife Sciences

A Look at Gerresheimer (XTRA:GXI) Valuation After FDA Approval of New On-Body Drug Delivery Device

Gerresheimer (XTRA:GXI) shares drew renewed attention after news that the US FDA approved the Lasix ONYU combination product, which features the company’s proprietary on-body drug delivery device. This regulatory win could prove commercially meaningful with 2025 launches approaching. See our latest analysis for Gerresheimer. Despite the lift from FDA approval of its new drug delivery device, Gerresheimer's share price has continued to face heavy pressure, with a 30-day share price return of...
XTRA:CHG
XTRA:CHGDiversified Financial

Should CHAPTERS Group’s Surging Sales and Deeper Losses Reshape Investor Views on XTRA:CHG?

CHAPTERS Group AG recently reported its earnings results for the half year ended June 30, 2025, posting sales of €70.96 million compared to €50.02 million in the prior year period and a net loss of €16.08 million versus €4.48 million previously. This earnings update highlights a substantial increase in sales alongside a much larger net loss, presenting a complex financial picture for the period. We’ll explore how the company’s simultaneous sales growth and increased losses reshape its...
XTRA:NDA
XTRA:NDAMetals and Mining

Will Aurubis (XTRA:NDA) Prioritize Dividends Over Growth With Its New Payout Strategy?

Aurubis AG approved a modified dividend policy on October 7, 2025, targeting a payout ratio of up to 30% of operating consolidated net income after taxes, starting with the 2025/26 fiscal year, and intends to apply a 25% payout ratio for fiscal year 2024/25 due to elevated investment activity. This updated approach signals a shift in management’s capital allocation priorities and may have meaningful implications for shareholder returns and future growth investments. We will examine how...